Xenetic Biosciences: Investor Presentation (Xenetic Biosciences) - Nov 19, 2016 - "ErepoXen was in general well tolerated. There was 1 Significant Adverse Event possibly related to ErepoXen in this cohort"; "9 of 14 patients were clear responders reaching therapeutic hemoglobin levels in 4 to 6 weeks"
P2 data • Biosimilar
|